Technological Advancements Driving Growth in the CGM Market
The Continuous Glucose
Monitoring (CGM) market is expected to reach $31.41 billion by 2031, growing at
a compound annual growth rate (CAGR) of 15.0% from 2024 to 2031. Key factors
driving this growth include the increasing prevalence of diabetes, sedentary
lifestyles, the advantages of CGM over traditional glucose monitoring, and the
adoption of CGM by athletes and fitness enthusiasts. Additionally,
technological advancements in CGM devices, a shift toward personalized care,
rising health awareness, and improved accessibility to diabetes care devices in
low and middle-income countries are anticipated to create significant
opportunities for market players.
Download free sample
report here: https://www.meticulousresearch.com/download-sample-report/cp_id=5960
Key Market Drivers
Increasing Prevalence of
Diabetes
CGMs offer continuous
glucose level monitoring and relay readings to healthcare providers via
smartphone apps. New product launches have enhanced diabetes management. For
example, in March 2024, the FDA approved Dexcom Stelo Glucose Biosensor System
by DexCom, Inc., an OTC integrated CGM for patients aged 18 and older,
particularly those not on insulin or without severe hypoglycemia. Factors like
obesity, poor diet, sedentary lifestyles, and genetic predispositions continue
to drive demand for effective glucose monitoring. The WHO reports approximately
422 million people globally have diabetes, highlighting the critical role of
continuous glucose monitoring.
Advantages of CGM Over
Conventional Monitoring
CGM devices provide
real-time data monitoring, trend analysis, alerts for abnormal glucose levels,
enhanced diabetes management, and reduce the need for fingerstick tests. The
integration of AI in CGM devices further optimizes diabetes management and lifestyle
adjustments. For example, in May 2023, January, Inc. launched an AI-supported
app predicting individual glucose patterns, offering recommendations on calorie
intake and physical activity, and providing tips on blood glucose management.
This app can be integrated with CGMs and accessed via smartphones, benefitting
even non-diabetic individuals on special diets.
Continuous Glucose
Monitoring Market Trends
Shift Toward Smart
Devices and Advanced Healthcare with Artificial Intelligence
The integration of AI in
glucose monitoring is a recent development. Smart CGM devices predict glucose
level fluctuations up to 60 minutes in advance and provide additional insights
for better glucose management. For instance, the Guardian Connect CGM System by
Medtronic allows users to track glucose patterns on mobile devices every 5
minutes. AI integration reduces the need for manual blood glucose checks,
predicting sugar levels and creating personalized diabetes management plans. In
March 2024, Roche launched the AI-powered 14-day Accu-Chek SmartGuide system,
predicting glucose level fluctuations.
Browse in depth: https://www.meticulousresearch.com/product/continuous-glucose-monitoring-market-5960
Continuous Glucose
Monitoring Market Opportunity
Technological
Advancements in CGM Devices
Technological
advancements in CGMs, such as wireless connectivity, personalized glucose
tracking, and AI and machine learning integration, are enhancing their
popularity. Enzyme-based electrochemical sensors in CGMs provide accurate and
reliable information. Wireless connectivity allows real-time glucose tracking
via smartphones, and integration with insulin pumps enables insulin level
adjustments based on glucose readings. Additionally, implantable CGMs, like the
Eversense® E3 by Senseonics Holdings, approved by the FDA in February 2022,
offer long-term glucose monitoring solutions.
Continuous Glucose
Monitoring Market Analysis: Key Findings
By Component: In 2024,
the Sensors Segment to Dominate the Continuous Glucose Monitoring Market
The sensors segment,
accounting for over 52.4% of the market, is expected to dominate due to the
preference for continuous glucose monitoring and frequent sensor replacements.
Disposable sensors are replaced every 7 to 14 days, while implantable sensors last
150-180 days.
Download request sample
report here: https://www.meticulousresearch.com/request-sample-report/cp_id=5960
By Age Group: In 2024,
the Adults Segment to Dominate the Continuous Glucose Monitoring Market
The adult segment is
projected to hold a larger market share due to the high prevalence of diabetes
and sedentary lifestyles among the geriatric population. According to NIDDK, in
2021, 38.4 million people had diabetes, with 38.1 million being adults aged 18
or older. The children segment is expected to register the highest growth rate,
driven by the increasing diagnosis of type 1 diabetes in children.
By End User: In 2024,
the Home Care Settings Segment to Dominate the Continuous Glucose Monitoring
Market
The home care settings
segment, expected to account for over 82.3% of the market, is driven by the
rising prevalence of diabetes, increasing health awareness, and the shift
toward preventive healthcare. CGM technologies are increasingly being adopted
in home care due to the shortage of healthcare professionals and growing
consumer awareness of diabetes monitoring.
Geographical Analysis
In 2024, North America
to Dominate the Continuous Glucose Monitoring Market
North America is
expected to hold the largest market share, over 42.2%, due to high
accessibility to advanced technologies, the presence of prominent
manufacturers, significant R&D investments, a robust reimbursement
framework, and supportive government initiatives. According to CMS, U.S.
healthcare spending reached $4.5 trillion in 2022. The Asia-Pacific region is
projected to register the highest CAGR of over 17.40%, driven by improving
healthcare infrastructure, rising disposable income, and increased investments
by major market players.
Quick buy: https://www.meticulousresearch.com/Checkout/64947495
Key Companies and Recent
Developments
Leading Players
Key players in the CGM
market include DexCom, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd,
Medtronic PLC, Nemaura Medical Inc., LifeScan, Inc., Senseonics Holdings, Inc.,
A. Menarini Diagnostics S.r.l, Medtrum Technologies, Inc., and B. Braun SE.
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment